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I. Introduction 
During the 2004 calendar year, health care expenditures accounted for 16 percent 
of GDP in the U.S., with this share twice as large as the corresponding value in 
1970 and predicted to exceed 20 percent by 2015.  Previous research has 
suggested that a key contributor to rising health care costs is the introduction and 
diffusion of new and more expensive treatments (Newhouse, 1992; Cutler, 
2004).1  To the extent that these treatments provide health benefits that are 
sufficiently large to justify the cost increases, there may be little cause for 
concern.  However, because most consumers of health care in the U.S. have 
health insurance, which partially or fully insulates them from price differences 
when choosing between alternative treatments, it is plausible that there is 
excessive use of certain treatments.2  Similarly, health care providers may have 
incentives to advocate for certain treatments over others, which could exacerbate 
or attenuate this phenomenon.3  Even absent these issues, both consumers and 
providers often have imperfect information about the effects of alternative 
treatments. 
As health care spending continues to grow, it is likely that the demand for 
better evidence regarding the effects of new treatments in real-world settings will 
increase (Garber, 2004).  At present, health care providers rely to a large extent on 
the results from random assignment clinical trials (RACTs), which are the 
dominant method for estimating causal relationships in medicine.  While these 
trials make important contributions to knowledge, they have a number of 
important limitations.  Perhaps most importantly, they rarely consider the effect of 
a treatment on expenditures but instead focus only on health effects.  
Additionally, results from the trials may not apply to real-world settings, where 
adherence to a treatment regimen may be different from in the controlled 
environment of an RACT.  Finally, RACTs are well-suited to estimating average 
effects but not how those effects vary across patients.  It is plausible that a 
treatment is very effective on average but has little effect on the margin, a 
phenomenon referred to as “flat of the curve medicine” (Fuchs, 2004).4 
                                                
1 Of course, new treatments can lower health care spending as well through health improvements 
that reduce the demand for other types of medical care (Lichtenberg, 2001). 
2 See Garber, Jones, and Romer (2006) for an analysis of why for similar reasons health insurance 
and certain regulatory features can lead to excessive innovation in this sector. 
3 See Kessler and McClellan (1996) for one such example, in which physicians respond a greater 
threat of being sued for malpractice by providing more treatments than their counterparts at lower 
risk. 
4 See Chan and Hamilton (2006) for a comprehensive discussion of the limitations of medical 
researchers’ analysis and interpretation of clinical trial data.  An additional limitation of clinical 
trials not mentioned in that study is that there can be placebo effects, which can lead to biased 
estimates as shown in a recent study by Malani (2006). 
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Researchers must therefore use alternative methods and data sources to 
estimate the impact of health care treatments in real world settings.  One possible 
strategy is to use data on health care utilization generated by government 
programs such as Medicaid and Medicare.  These claims data sets have the 
advantage of large sample sizes, which can be important for obtaining precise 
estimates of treatment impacts.  They also have the advantage of capturing 
treatment patterns in the real world. 
The key obstacle to obtaining reliable estimates when using claims data is 
that treatment is endogenous.  Individuals who take a certain treatment may differ 
in important ways from their observably similar counterparts who do not.  
Previous researchers have accounted for this issue in a variety of ways.  One 
prominent study used a patient's distance from a hospital as a source of variation 
in treatment (McClellan et al, 1994).  In that study, the authors demonstrate that 
individuals who live closer to the hospital are more likely to receive intensive 
treatment, and use this variation to estimate the marginal effect of invasive 
treatments.  However, as the authors note, this method is not well-suited to 
estimating the average effect of a health care treatment. 
In this paper, we propose an alternative approach to estimating the effect 
of health care treatments that allows us to estimate the average effect of a new 
treatment soon after its introduction and how the effect varies across individuals.  
More specifically, we use several years of claims, eligibility, and mortality data 
from California’s Medicaid program to estimate the effect of new HIV 
antiretroviral treatments (ARVs) on both health care spending and health 
outcomes. 
We select these treatments as our case study for three main reasons.  First, 
these treatments are differentially used by beneficiaries of the Medicaid program, 
with almost half of U.S. residents with HIV/AIDS insured by Medicaid 
(Bhattacharya et al, 2003), and thus our estimates are more likely to be reflective 
of overall impacts. Second, several RACTs have demonstrated the average health 
benefits of ARVs, and thus we have a baseline against which we can compare our 
estimates.  To the extent that we replicate the RACT results for average health 
effects, we can be more confident that our estimates for spending and for how 
both health and expenditure effects vary across individuals are accurate.5  And 
finally, because these treatments diffused rapidly, our estimates are less likely to 
be contaminated by changes in the population of individuals with HIV/AIDS. 
We account for endogenous treatment decisions in two ways.  First, we 
                                                
5 It is important to note that here we do not consider producer surplus, which as Philipson and Jena 
(2006) point out can lead to underestimates of the benefits of new medical technologies.  
However, their estimates for ARVs suggest that the value of consumers' health benefits exceeded 
producer surplus by a factor of twenty, and thus at least for this category of treatments we are 
omitting only a small fraction of the social benefit. 
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utilize data from before and after the introduction of several new ARVs and 
exploit the fact that there were sharp changes in their use immediately following 
their approval.  By controlling for the pre-existing trends in our outcome variables 
of interest, we can obtain credible estimates for the average short-term effect of 
these treatments as they are rapidly diffusing.  Second, we utilize the detailed 
information on health care utilization to construct proxies for health status.  This 
allows us to estimate the variation across individuals in effectiveness of treatment 
by comparing individuals who take the treatments with their observably similar 
counterparts from the period just prior to FDA approval. 
An analysis of trends in the average values of our key outcome variables 
of interest demonstrates that, prior to the approval of Epivir and three protease 
inhibitors (hereafter Epivir/PI) in late 1995, quarterly mortality rates and average 
spending among California Medicaid recipients with HIV/AIDS were fairly stable 
at 7 percent and $5400, respectively.  But within 1.5 years of the approval of 
Epivir/PI, the fraction of our sample taking one or more of these ARVs had 
increased to almost 60 percent while the quarterly mortality rate had fallen to 2 
percent.  This decline coincides closely with trends at the national level, 
suggesting that the low-income beneficiaries of the Medicaid program were 
approximately as successful as other U.S. residents with HIV/AIDS in complying 
with the recommended treatment regimen.  During the same period, average 
quarterly Medicaid expenditures declined by almost $400, with a substantial 
increase in prescription drug spending more than offset by spending on 
hospitalizations and other health care services. 
While these changes in average outcomes are striking, they shed little light 
on the extent to which the effects varied across individuals.  We therefore next 
turn to individual-level data, where we demonstrate that controlling for pre-
treatment health status substantially increases our estimate for the average effect 
of the treatments on mortality probabilities.  Moreover, we uncover substantial 
heterogeneity in this effect, with the sickest patients deriving the largest health 
benefits.  Our findings for the effect of the treatments on expenditures also reveal 
substantial heterogeneity, with large reductions in spending for the sickest 
patients but significant increases for healthier patients.  The mechanism for this is 
that the use of the new treatments increased pharmaceutical spending but reduced 
the need for hospitalizations and other types of medical care.  Healthier patients 
had little other medical care to offset and thus the increase ARVs increased total 
spending on them. 
In the final section of our paper, we investigate the effect of the new 
treatments on long-term Medicaid spending, life expectancy, and the 
corresponding cost per life-year saved.6  The new treatments reduced quarterly 
                                                
6 These treatments may have influenced other outcome variables as well.  For example, 
Lakdawalla et al. (2006) find that ARVs increase risky behavior such as unprotected sex and 
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Medicaid spending by an average of 16 percent but increased life expectancy by a 
factor of three.  Combining these two effects leads us to estimate the cost per life 
year saved of the four treatments introduced in late 1995 and early 1996 at close 
to $19,000, well within the range of what is considered to be cost effective. 
The results from this study suggest an alternative method for utilizing 
claims data to evaluate the impact of new health care treatments on both spending 
and health.  This method is most well-suited to evaluating the effect of treatments 
that diffuse rapidly such as the ARVs considered here.  
II. Background on HIV/AIDS and Antiretroviral Treatments 
AIDS is a chronic disease that damages, and ultimately destroys, an individual’s 
immune system.  AIDS is caused by HIV, an infection that kills the body’s "CD4 
cells", a type of white blood cell that helps the body fight off infections.  When 
this epidemic first appeared, providers could only treat opportunistic illnesses 
resulting from the weakened immune system rather than attack the virus itself.  
This changed with the entry of Retrovir (AZT) to the market in 1987. This drug 
was the first one approved by the FDA in the therapeutic class known as NRTIs 
(nucleoside reverse transcriptase inhibitors).  Despite the entry of three additional 
NRTIs from 1991 to 1994, use of these drugs among AIDS patients actually 
declined from 1992 through 1995.  This trend reversed following the approval of 
Epivir and three drugs from a new class known as protease inhibitors (PIs) in late 
1995 and early 1996.  The first NNRTI (non-nucleoside reverse transcriptase 
inhibitor) was approved in June of 1996.  Twelve additional drugs were approved 
in the seven years from 1997 to 2003 (Table 1). 
The release of Epivir/PI spawned the use of highly active antiretroviral 
therapy (HAART), which is the simultaneous use of two or more ARVs to treat 
HIV.  The optimal time to initiate HAART depends both on the strength of the 
patient’s immune system and on the concentration of HIV in the patient’s blood. 
Current guidelines recommend HAART for all patients with less than 200 CD4 
cells per cubic millimeter of blood and suggest that all patients with CD4 cell 
counts between 200 and 350 be offered treatment (NIH, 2004; Yeni et al., 2002).  
Thus those HIV-positive individuals who take the drugs will tend to be sicker 
than their counterparts who do not.   In a short period after the approval of 
Epivir/PI, HAART became the standard treatment for those infected with HIV.  
The sharp increase in the use of the drugs coincided with a substantial decline in 
the mortality rate among AIDS patients.7  According to data from the U.S. 
                                                                                                                                    
intravenous drug use.  While important, we consider these outcomes and some others (e.g. 
pharmaceutical firm profits) to be outside the scope of the current study. 
7 Individuals with HIV are defined as having AIDS once their CD4 count falls below 200 or once 
they are diagnosed with an AIDS-defining illness. The main benefit of starting HAART early is 
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Centers for Disease Control, the mortality rate for individuals with AIDS fell by 
70 percent between 1995 and 1998. 
A large number of studies, some using randomized research designs 
(Hammer et al., 1997; Delta Coordinating Committee, 2001; Floridia et al., 2002) 
and others using observational data with detailed clinical information (Palella et 
al., 1998; Detels et al., 1998; CASCADE Collaboration, 2003) investigated the 
life saving benefits of the new ARVs.8   All of these studies found that the new 
treatments generated statistically significant reductions in mortality.  For example, 
in an RACT examining the effectiveness of one protease inhibitor in combination 
with Retrovir and Epivir, Hammer et al. (1997) found that 48-week mortality rates 
were 55 percent lower among those taking a protease inhibitor.  Palella et al. 
(1998) used observational data for 1255 patients in eight U.S. cities to examine 
the impact of ARVs on mortality.  Controlling for demographic characteristics 
and CD4 count levels prior to treatment, the authors found that mortality fell by 
more than 70 percent among those using protease inhibitors with two or more 
NRTIs.9 
Demonstrating that we could replicate the results from RACTs or studies 
with more detailed clinical information would potentially expand the types of 
questions that can be addressed with claims data.  We therefore view estimates 
from these previous studies as a useful benchmark.  If the treatments are similarly 
effective for those on Medicaid and if these individuals adhere well to the 
treatment regimens then we should detect a similar average mortality effect. 
                                                                                                                                    
that it can prevent both the degradation of the immune system and the elevation of viral loads.  
The main costs are that patients often experience severe side effects and they can also develop 
drug resistance, thereby reducing future treatment options. 
8 Lichtenberg (2003) uses aggregate, national-level data for the U.S. to estimate the effect of ARV 
approvals. 
9 There are no RACTs of which we are aware that compare the use of both Epivir and PI with the 
use of neither. 
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Table 1: Prescription Drugs Approved for Treatment of HIV Infection by 12/31/03 
    
  FDA 
First script 
in  
Class 
Brand 
Name Appr. Date claims data Ingredients 
NRTI Retrovir 3/19/1987 1/2/1993 zidovudine 
NRTI Videx 10/9/1991 1/4/1993 didanosine 
NRTI Hivid 6/19/1992 1/4/1993 zalcitabine 
NRTI Zerit 6/24/1994 8/6/1994 stavudine 
NRTI Epivir 11/17/1995 11/27/1995 lamivudine 
NRTI Combivir* 9/27/1997 10/17/1997 lamivudine, zidovudine 
NRTI Ziagen 12/17/1998 12/18/1998 abacavir 
NRTI Trizivir** 11/14/2000 12/1/2000 abacavir, zidovudine, lamivudine 
NRTI Viread 10/26/2001 11/1/2001 tenofovir disoproxil fumarate 
NRTI Emtriva 7/2/2003 7/16/2003 emtricitabine 
PI Invirase 12/6/1995 12/11/1995 saquinavir mesylate 
PI Norvir 3/1/1996 3/7/1996 ritonavir 
PI Crixivan 3/13/1996 3/26/1996 indinavir 
PI Viracept 3/14/1997 3/19/1997 nelfinavir mesylate 
PI Fortovase 11/7/1997 11/18/1997 saquinavir 
PI Agenerase 4/15/1999 4/26/1999 amprenavir 
PI Kaletra 9/15/2000 9/20/2000 lopinavir and ritonavir 
PI Lexiva 10/20/2003 11/11/2003 fosamprenavir calcium 
NNRTI Viramune 6/21/1996 8/10/1996 nevirapine 
NNRTI Rescriptor 4/4/1997 4/25/1997 delavirdine 
NNRTI Sustiva 9/17/1998 9/23/1998 efavirenz 
FI Fuzeon 3/13/2003 4/8/2003 enfuvirtide 
Source for drug list and approval dates: US FDA at http://www.fda.gov/oashi/aids/virals.html 
* Combivir is a combination of Epivir and Retrovir 
** Trizivir is a combination of Epivir, Retrovir, and Ziagen 
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III. Constructing the Analysis Files 
A. The California Medicaid Claims and Eligibility Data 
We utilize claims and eligibility data for a random 24 percent sample of Medicaid 
recipients from the state of California to estimate the effect of ARVs.  Individuals 
can qualify for the means-tested Medicaid program through several different 
channels, with the most common reasons in California being the receipt of 
Temporary Assistance to Needy Families (TANF) or Supplemental Security 
Income (SSI) benefits.  In our data there are 4.03 million people eligible for 
Medicaid in at least one month from 1993 to 2003.  The eligibility files contain 
demographic information including gender, month and year of birth, and race.  
Additionally, there are two variables in each month that allow us to determine 
whether each individual is dually eligible for health insurance through Medicare 
or enrolled in a Medicaid managed care plan.10 
The claims data includes all fee-for-service payments made from January 
of 1993 until June of 2004, though because there is often a lag in processing the 
claims, we consider utilization through the end of 2003.  There are three types of 
claims in our data.  Inpatient claims are generated for admissions to hospitals and 
long-term care facilities and include information about the patient’s primary and 
secondary diagnosis, the dates of service, and the amount paid by Medicaid.  
Outpatient claims have similar data about payments to physicians, emergency 
rooms, and other health care providers. Finally, prescription drug claims provide 
data on payments made to pharmacies for drugs covered by Medicaid.  Each 
pharmacy claim includes an eleven-digit National Drug Code that allows us to 
determine the drug and the dosage amount.  All three types of claims include the 
patient’s Medicaid identifier (an encrypted social security number), which we 
match to the eligibility files. 
Finally, our claims and eligibility data11 has been merged to death records 
from the California Center for Health Statistics for the 1993 through 2001 period.  
These records identify date and cause of death for all California residents, though 
8 percent of our sample cannot be linked because they do not have a valid 
(encrypted) social security number. 
B. Defining the HIV/AIDS Sample 
A number of previous researchers have used Medicaid claims data to construct 
samples of HIV/AIDS patients (Eichner and Kahn, 2001; Morin et al., 2002).  
                                                
10 Many Medicaid recipients are also eligible for Medicare, either because they are over the age of 
65 or because they receive benefits from the Social Security Disability Insurance program. 
11 This data was obtained from the California Department of Health Services' Medical Care 
Statistics Section.  See Duggan (2005) for a detailed description of this data.  There is a 24 percent 
sample because the 20 and 5 percent samples that the state provides partially overlap. 
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Following this research, we use ICD-9 diagnosis codes on the Medicaid inpatient 
and outpatient claims to determine whether individuals are diagnosed with this 
illness.  To reduce the possibility of false positives, we restrict attention to patients 
with two or more non-prescription HIV/AIDS claims.12  This algorithm yields a 
sample of 12,932 individuals who have one or more HIV/AIDS claims, are 
eligible for Medicaid at some point during our study period, have a valid social 
security number, and have consistent age and gender information across years in 
the eligibility files.13 
Although our Medicaid claims data contain a rich set of information, it 
does have some important limitations. First, our data is for just one state and thus 
our results may not generalize to Medicaid recipients elsewhere in the country.  
Second, we lose patients who temporarily or permanently exit because they 
become ineligible for Medicaid.14  Third, we do not know when patients were first 
diagnosed with HIV or AIDS but instead only the date of their first Medicaid 
HIV/AIDS claim during our study period.  Fourth, claims data do not contain 
diagnostic information about patients such as CD4 cell counts or HIV viral loads.  
This information is important because it indicates who is recommended to receive 
ARVs.   Fifth, we do not have Medicare expenditure data for people also eligible 
for that program and we will therefore understate health care expenditures by the 
government for this group.15  And sixth, we have incomplete utilization data for 
patients enrolled in a Medicaid managed care plan and thus exclude them from 
our analyses. 
One final limitation to our analysis sample that must be considered in the 
results that follow is that we only have data for Medicaid recipients.  While 
Medicaid insured approximately half of all California residents with HIV/AIDS 
during our study period (Bhattacharya et al., 2003), our sample does not include 
individuals who are uninsured or receive health insurance from another source.  
Perhaps the most relevant source for a person prior to or immediately following 
his/her enrollment in Medicaid is the AIDS Drug Assistance Program (ADAP), 
which was introduced in 1996.  This program subsidizes the purchase of ARVs 
for low-income individuals who are without another source of health insurance.  
Because the introduction of this program may have affected the entry to or exit 
from the Medicaid program, we estimate several specifications below that restrict 
                                                
12 False negatives are also a possible concern, though as we describe below the number in our 
sample is similar to what we would expect given that approximately half of California residents 
with HIV/AIDS are on Medicaid. 
13 Research by Rosenblum et al., (1993) using Medicaid claims data has found that this algorithm 
captures the vast majority of recipients diagnosed with HIV/AIDS. 
14Fewer than 2 percent of the sample exits the sample per quarter and this exit rate declines during 
our study period.  For example it falls from 1.96% in the last quarter of 1995 to 1.42% in the first 
quarter of 1998. 
15 Medicare did not cover prescription drugs for dual eligibles during our study period. 
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only to those enrolled in Medicaid and diagnosed with HIV in the year prior to the 
introduction of ADAP.16 
C. Sample Characteristics 
On the left-hand axis in Figure 1, we plot the number of Medicaid recipients in 
our sample who were alive at the beginning of half-year periods starting in 
January of 1994.  The patients in each half-year cell had their first HIV/AIDS 
claim by the end of that period although they may have been enrolled in Medicaid 
for some time before that date.  Roughly one-fourth of the sample appears in the 
first half-year of the time period and the sample grows steadily after that date.  On 
the right-hand axis of the figure, we graph the total number of people living with 
AIDS in California17 at the end of each six month period as reported by the U.S. 
Centers for Disease Control in their publication HIV/AIDS Surveillance Report.  
These two series track one another quite closely.  Our numbers suggest that 
roughly 52 percent of people living with AIDS in California are on Medicaid,18 a 
number close to the national average (Bhattacharya et al., 2003).  Similarly the 
number of individuals in our sample grows at an almost identical rate to the 
statewide total (58 percent for both from 1994 to 2001).  Given the possible 
limitations with using claims data outlined above, our algorithm for identifying 
Medicaid recipients with HIV/AIDS appears to work quite well.19 
                                                
16 The ADAP program gave some states an incentive to change the stringency of their Medicaid 
eligibility requirements. Recent research suggests that states with more stringent Medicaid 
eligibility thresholds had higher mortality rates among affected individuals with HIV/AIDS 
(Ghosh et al, 2007).  
17 We should note that our sample includes not only patients with AIDS but also some who are just 
HIV-positive.  Unfortunately, in most years California only reported to the CDC the number of 
people living with AIDS, not the number with HIV.  Thus in one respect it is plausible that the 
patients in our sample would be healthier than the typical AIDS patient in California.  However, 
most of the individuals in our sample qualify for Medicaid through the means-tested Supplemental 
Security Income (SSI) program.  Thus they must be in relatively poor health to meet SSI’s medical 
eligibility criteria.  As we document below, the death rates for our sample are substantially higher 
than for non-Medicaid AIDS patients in California.  Therefore, comparing trends in the number of 
HIV/AIDS patients on Medicaid to overall trends of AIDS patients seems a reasonable 
compromise given the available data. 
18 Consider the first half of 1994 when there are 3,237 individuals in our sample.  To estimate the 
number on Medicaid with HIV/AIDS one must multiply this by (1/.24).  Additionally we must 
multiply by 1.058 to account for the exclusion of those with an invalid SSN.  This yields 14,270, 
which is 52.0% of the statewide total of 27,454. 
19 One possible concern with focusing just on Medicaid recipients is that the incentive to enroll in 
the program will change after new treatments become available (Goldman et al., 2001), raising the 
possibility of composition bias.  The fact that our series tracks closely with the total number in the 
state suggests this is not too problematic. 
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Figure 1:  HIV/AIDS Cases in the 24% Medicaid Sample and # Living with AIDS in CA
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In Figure 2, we graph half-year mortality rates for the Medicaid recipients 
in our sample during the 1994-2001 period and compare this with the 
corresponding mortality rate among all California AIDS patients.  Death rates in 
our sample are approximately 2 percentage points higher on average, indicating 
that Medicaid recipients are in worse health.  Additionally, the timing and 
magnitude of the declines in mortality for the two groups are similar. 
In Table 2, we report descriptive information for our sample in four years:  
1994, 1997, 2000 and 2003.  In constructing this sample we drop the 1,063 
individuals who live in one of the eight counties that moved its Medicaid 
recipients into a county-organized health system during our study period because 
our claims data would often be incomplete for them.  We also drop the 1,802 
individuals with one or more months in a Medicaid managed care plan during our 
eleven-year study period.20  This leaves us with a final sample of 10,067 
HIV/AIDS patients.  As the table shows, the annual mortality rate in the sample 
fell from 23.0 percent in 1994 to 5.2 percent in 2000, contributing to a large 
increase in the average age of the sample. The fraction of the population under 40 
                                                
20 The lack of data for patients in managed care could be problematic if it leads to changes in the 
composition of our sample over time, though the fact that the number of individuals in our sample 
tracks the number statewide with AIDS quite closely (Figure 1) suggests that this issue is not too 
problematic. 
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fell from 50 percent in 1994 to 28 percent nine years later.  During our study 
period the fraction of the sample that is black and female increased by 47 and 19 
percent, respectively. 
In the bottom half of the table, we report information about health care 
utilization in our sample.  Almost 48 percent of our sample had an inpatient stay 
in 1994 and this number fell to 28 percent during the next nine years.  Annual 
inpatient spending fell by an even larger percentage from $7125 to $3510.  In 
contrast, annual outpatient spending increased slightly while spending on 
prescription drugs tripled, driven primarily by the increased use of ARVs.   
Although average annual spending on prescription drugs increased by $8,000 by 
the end of the study period in 2003, total annual spending increased by just 
$4,800.21  The fraction of HIV/AIDS patients who are eligible for Medicare 
increased from 28 to 45 percent, with this change likely contributing to the fall in 
Medicaid spending on inpatient care given that Medicare covers most inpatient 
costs for dual eligibles. 
Figure 2: Half-Year Mortality Rate for AIDS Patients
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21 Expenditure data cited here and elsewhere in the paper are adjusted to December, 2001 dollars 
using the Bureau of Labor Statistics' Consumer Price Index for Urban consumers (CPI-U). 
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Table 2: Summary Statistics for the Medicaid HIV/AIDS Sample 
 1994 1997 2000 2003 
Average Age 38.4 40.7 43.0 45.1 
% Ages 0-17 2.5% 2.6% 2.5% 2.2% 
% Ages 18-29 12.0% 8.5% 4.4% 3.8% 
% Ages 30-39 44.1% 38.7% 32.0% 21.9% 
% Ages 40-49 29.3% 33.1% 37.7% 41.8% 
% Ages 50-64 10.0% 13.4% 19.2% 25.3% 
% Ages 65+ 2.1% 3.8% 4.3% 4.9% 
% Black 21.1% 23.4% 24.5% 25.0% 
% Female 15.2% 21.3% 21.8% 22.3% 
Inpatient Spending 7125 4309 3900 3510 
Outpatient Spending 5091 4870 5007 5455 
RX Spending 4122 7769 11913 12120 
Total Spending 16338 16948 20820 21084 
% Die in Year 23.0% 7.5% 5.2% - 
% Any Inpatient 47.8% 39.8% 30.0% 27.9% 
Eligible Months 8.9 10.1 10.4 10.8 
% Medicare 28.0% 39.2% 43.3% 44.7% 
# in Sample 3221 3687 4275 4976 
    
     
     
     
IV. The Impact of HIV Antiretroviral Treatments: A Graphical Presentation 
The FDA’s approval of Epivir in November of 1995 and of three protease 
inhibitors during the next four months coincided with a sharp decline in the 
mortality rate among the Medicaid recipients in our sample.  As Figure 2 
demonstrates, from the latter half of 1995 to the same period in 1997, the six-
month mortality rate among California Medicaid recipients diagnosed with 
HIV/AIDS fell by 70 percent, from 11.3 to 3.4 percent.  During the next four 
years the mortality rate in our sample declined gradually and was equal to 2.8 
percent in the second half of 2001. 
Figure 3 depicts the fraction of individuals in the sample filling at least 
one prescription for an ARV in the quarter.  From the third quarter of 1995 to the 
second quarter of 1997, this fraction more than doubled, increasing from 29 to 59 
percent.  As Figure 4 shows, this growth was driven by an increase in the use of 
Epivir/PI, with 56 percent of our sample taking one or more of these treatments in 
the second quarter of 1997.  There were no significant changes in utilization for 
Includes Medicaid-eligible individuals in the 24 percent CA sample with 1 or more 
HIV/AIDS claims in current or previous year.  Excludes those with one or more 
months in a Medicaid managed care plan or in one of the eight counties with a 
county-organized health system.  
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other ARVs. Taken together, the series depicted in Figures 2, 3, and 4 strongly 
suggest that Epivir/PI was the primary cause of the sharp decline in mortality 
rates observed during our study period.  
This is more easily represented in Figure 5, where on the left vertical axis, 
we report the fraction of patients that are using either Epivir or protease inhibitors, 
and on the right vertical axis, we report the patient quarterly mortality rate.  There 
are three things to highlight in this graph.  First, notice that prior to the first 
quarter of 1996, quarterly mortality rates had been trending down slightly.  
Second, as Epivir/PI use increased from zero to 56 percent between the fourth 
quarter of 1995 and the second quarter of 1997, quarterly mortality rates fell by 
72 percent, from 6.7 percent to 2.0 percent.  As Epivir/PI use stabilized in mid-
1997, so did mortality rates.  Between mid 1997 and the end of our study period, 
mortality rates varied between 1.4 and 2.0 percent with no obvious trend. 
Figure 3: Fraction of CA Medicaid Sample Taking 1+ HIV Drugs in Each Quarter
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Figure 4: Diffusion of Epivir and Protease Inhibitors: 1994Q1 - 2003Q4
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Figure 5: Quarterly Mortality Rate and Use of PI/Epivir
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The potential importance of Epivir/PI as an explanation for the decline in 
mortality is most easily illustrated with a simple time series model in which we 
regressed the first-difference in quarterly mortality rates on the first difference in 
quarterly Epivir/PI use among HIV/AIDS patients in our sample during the 1994-
2001 period.  The coefficient on the change in Epivir/PI use is -0.079 (with a 
standard error of 0.015), which implies an average reduction of 7.9 percentage 
points in the quarterly mortality rate.22  This is actually greater than the mortality 
rate in our sample just prior to the approval of these treatments, which is not so 
surprising given that the individuals who took the new ARVs are likely to have 
been in worse health and thus have higher baseline mortality rates. 
Given the major improvements in health resulting from the use of 
Epivir/PI, it is plausible that the treatments partially or fully paid for themselves 
by reducing the demand for hospitalizations and other health care services.  
Figure 6 plots average Medicaid spending in our sample along with average 
spending on both prescription drugs and all other health care services.  As is clear 
from the figure, average spending on prescription drugs increased substantially 
following the introduction of Epivir/PI, increasing from $1391 in the third quarter 
of 1995 to $2505 just two years later.  But spending on all other services fell by 
an even greater amount, so that average quarterly spending declined by 8 percent 
($5401 to $5030) from late 1995 to 1997.  As we demonstrate below, this change 
in average Medicaid expenditures masks important changes in its overall 
distribution. 
We also investigated whether the treatments affected the quarterly exit rate 
from the program for reasons other than mortality (e.g. return to work) and found 
little evidence to support this as shown in Appendix Figure 1.  This is especially 
true in the two years just after the approval of Epivir-PI.  This suggests that the 
composition of our sample is not changing too dramatically during the period that 
is the focus of our empirical analysis.23 
                                                
22 It is worth noting that many taking Epivir and/or a protease inhibitor were also taking one or 
more other ARVs.  Thus our estimates may to some extent be capturing the effect of a 
combination of new and existing treatments. 
23 One noteworthy change shown in Table 2 is in the fraction of the sample that is female, which 
increased from 15 to 21 percent from 1994 to 1997.  However, this fraction was already trending 
up prior to the approval of Epivir-PI. 
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Figure 6: Average Quarterly Spending in the Medicaid HIV/AIDS Sample
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V. The Impact of the New Treatments on Mortality: Individual-Level 
Evidence 
In this section we estimate the impact of Epivir/PI use on mortality using 
individual-level claims data.  There are two key factors we must consider when 
constructing an econometric model.  First, individuals who are in worse health are 
both more likely to die and to use these treatments.  Failing to account for this 
would lead us to underestimate the health benefits of the treatments.  Second, the 
effect of the treatment is likely to vary across individuals, with more severe 
patients deriving greater benefits.  These two considerations motivate a model of 
the following type for the effect of taking a treatment Z in the current period on 
health status H in the next period: 
1,1, **)(*)1( ++ +++= tjjtjtjtjttj XZHHH εθγμ
In this equation, Hjt represents individual j’s health status in period t and Zjt is an 
indicator that equals one if person j takes the treatment in period t and zero 
otherwise.  The average effect of the treatment is assumed to vary only with the 
individual’s health status according to the function )( jtHγ 24.  Other background 
                                                
24 We define this function below to include both a "main effect" and an effect that varies linearly 
with health status. 
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characteristics such as gender, age, and race, all of which are potentially 
important determinants of changes in health status, are controlled for in the vector 
Xjt.   
A. Estimating Health Status 
To construct a proxy for health status Hjt, we exploit the diagnosis and treatment 
information contained in our Medicaid claims data.  We recognize that our data is 
not perfect for this, as it does not include detailed clinical information such as 
CD4 counts or viral loads.  Our data does however contain a record of every 
health care treatment paid for by the Medicaid program for the individuals in our 
sample.  In this section, we investigate whether the claims data can capture 
variation across individuals in their mortality probabilities in the period just prior 
to the release of Epivir/PI.  To the extent that this is successful, we can then use 
these predicted probabilities to investigate differences in the utilization and in the 
impact of Epivir/PI as suggested by equation (1). 
We are especially interested in the severity of each individual's HIVAIDS 
illness, as this is by far the most common cause of death for the individuals in our 
sample prior to the introduction of Epivir/PI and will influence whether 
individuals are encouraged to take Epivir/PI soon after it becomes available.  We 
therefore focus attention on inpatient and outpatient claims with a primary or 
secondary diagnosis of HIV/AIDS when estimating linear probability models of 
the following form: 
1,132101, _*_*_*)2( +++ +++++= tjtjtjtjttj PAIDHIVOPHIVIPHIVD εωββββ
In this model, the variable 1, +tjD  is equal to 1 if individual j dies in quarter t+1 
and zero otherwise.  The variables HIV_IPjt and HIV_OPjt represent the number 
of inpatient and outpatient claims, respectively, with a primary or secondary 
diagnosis of HIV/AIDS for person j in quarter t.  Individuals with more severe 
cases of HIV/AIDS would presumably have more contact with the health care 
system and thus more Medicaid claims.  Of course, not all claims are equal, with 
some reflecting payment for intensive services (e.g. emergency room visits or 
hospital stays) and others simply payment for annual checkups.  In an effort to 
account for this, we also include a variable HIV_PAIDjt, which is equal to total 
Medicaid spending (in thousands of dollars) for inpatient and outpatient claims 
with a primary or secondary diagnosis of HIV/AIDS.25 
We estimate this model using data for all four quarters of 1994, 
approximately one year prior to the introduction of Epivir/PI.  The number of 
individuals in this estimation sample is 2781 and the number of observations is 
                                                
25 Our results in this section and in the subsequent sections were very similar if we used a richer 
set of utilization controls to predict quarterly mortality rates. 
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7854. 26  The estimates for β1, β2, and β3 using 1994 data are .0332 (se = .0126), 
.0027 (se = .0003), and .0034 (se = .0015), respectively, with the estimate for β0 
of .0426 (se = .0031).  All three estimates are positive and statistically significant, 
suggesting that our utilization measures capture important dimensions of health 
status.  We then use the coefficient estimates from equation (2) to calculate a 
predicted quarterly mortality probability – our proxy for health status - for each 
individual in the sample in every one of the next eight quarters.  This two year 
period (from the first quarter of 1995 to the final quarter of 1996) includes the 
period leading up to and immediately following the introduction of Epivir/PI and 
is the focus of our subsequent analyses. 
Before proceeding to these analyses, we test the predictive power of our 
proxy in two ways.  We first investigate whether it is significantly positively 
related with quarterly mortality outcomes just prior to the release of Epivir/PI by 
estimating specifications of the following type using data from the first three 
quarters of 1995: 
1,11,1,
ˆ)3( ++++ +++= tjtjttjtj XDD ξπφλ
In this equation, 1,ˆ +tjD  is individual j’s predicted mortality probability in quarter 
t+1 and 1, +tjD  is the actual mortality outcome for j in that same quarter, which 
equals one if the person dies in quarter t+1 and zero otherwise. The vector jtX  
includes a set of control variables for the person’s age, gender, race, and Medicare 
eligibility. 1+tπ  represents a set of eight indicator variables for each quarter that 
we consider to control for common changes over time in mortality probabilities.  
The equations are estimated as linear probability models. 
The results presented in the first column of Table 3 demonstrate that our 
proxy for HIV/AIDS severity is a powerful predictor of mortality during the 1995 
calendar year.  Specifically the coefficient estimate for λ  is 1.042 (t-statistic of 
11.2) and is not significantly different from 1.  Interestingly there are also 
statistically significant differences in mortality probabilities by age and gender, 
even after controlling for our measure of health status.  For example, women are 
significantly less likely to die and the mortality probability generally increases 
with age. 
                                                
26 For a particular person-quarter observation to be included in this estimation sample, the person 
must be eligible for Medicaid during all three months in the quarter and still be alive at the end of 
the quarter. 
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Table 3: Determinants of Mortality and of Epivir/PI Utilization 
  
 Mortality  PI-Epivir 
 (1)  (2) 
HIV Severity 1.042***  0.979*** 
 (0.093)  (0.129) 
Female -1.557**  -0.124*** 
 (0.658)  (0.019) 
Black -0.113  -0.126*** 
 (0.675)  (0.018) 
Age 15-24 -2.621**  -0.198*** 
 (1.050)  (0.043) 
Age 25-34 -1.385**  -0.021 
 (0.663)  (0.018) 
Age 45-54 1.515*  0.002 
 (0.886)  (0.022) 
Age 55-64 1.141  -0.074** 
 (1.464)  (0.035) 
Age 65+ -1.312  -0.302*** 
 (1.358)  (0.042) 
Medicare 0.812  0.126*** 
 (0.635)  (0.017) 
Quarters Included 95Q1-95Q3  96Q1-96Q4 
# Observations 6504  10523 
Quarter Effects? Yes  Yes 
R-squared 0.0779  0.0986 
Mean of Dep Var 0.062  0.428 
# of Individuals 2711  3280 
   
  
  
We next investigate whether – as expected – 1,ˆ +tjD  is significantly 
positively related with the likelihood that an individual in our sample takes 
Epivir/PI during the 1996 calendar year.  To examine this question, we estimate a 
model similar to equation (3) but use as the outcome of interest an indicator that 
equals 1 if person j was taking either Epivir/PI in quarter t+1.  The coefficient 
Sample includes all individuals with one or more HIV/AIDS claims in the quarter or 
in a previous quarter and who are eligible for Medicaid and still alive at the end of 
the quarter.  Unit of observation is the person-quarter.  All specifications are 
estimated as linear probability models and include quarter fixed effects.  Standard 
errors are clustered by individual.  
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estimate on the predicted mortality probability 1,ˆ +tjD  of 0.979 (t-statistic of 7.6) 
displayed in the second column of Table 3 reveals that sicker patients were the 
ones most likely to select into the new treatment following its release.  The results 
presented in this column also demonstrate that there are significant differences by 
gender, age, and race in the takeup of the new treatments. 
The results described in this section demonstrate that the Medicaid claims 
data can be used to estimate the health status of individuals with HIV/AIDS.  We 
next use this proxy to estimate the effect of the new pharmaceutical treatments 
released in late 1995 and early 1996 on mortality outcomes and the extent to 
which this effect varied across individuals. 
B. Individual-Level Estimates 
In this section we estimate the effect of Epivir/PI on mortality outcomes for the 
individuals in our sample.  We focus on the two year period from the first quarter 
of 1995 to the final quarter of 1996.  This gives us four quarters of information 
prior to the introduction of Epivir/PI and four quarters when the new treatments 
were rapidly diffusing.  There are four reasons for focusing on this two-year 
period even though we have several more years of data.  First, it allows us to 
contrast outcomes for individuals with HIV/AIDS prior to the introduction of the 
new treatments with their observably similar counterparts one year later.  Second, 
it is readily apparent from the trends in mortality that this period is the most 
important one, with mortality rates falling by almost 60 percent in the year 
following the release of Epivir/PI.  Third, there were no other HIV treatments 
released in 1995 and 1996, except for one that had very low utilization (1.0 and 
3.3 percent in the third and fourth quarters, respectively, of 1996).  This reduces 
the possibility that changes in other treatment patterns might bias our results.  The 
fourth and most important reason is that, once the new treatments were released, 
the distribution of health status in our Medicaid sample begins to change rapidly.  
As a result of this, the relationship between treatment patterns and health status 
may also have changed, which would lead our proxy to be a less reliable measure 
of health over time. 
  To estimate the effect of Epivir/PI on mortality, we estimate specifications 
that allow the effect of the treatment to vary across individuals as a function of the 
predicted mortality probability 1,ˆ +tjD .  Specifically, we assume that the treatment 
effect γ from equation (1) above is a linear function of an individual's predicted 
mortality probability when estimating linear probability models of the following 
type: 
1,11,31,211,
ˆ**ˆ**)4( +++++ +++++= tjtjttjjttjjttj XDEDED ξωρθθθ
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In this equation, jtE is equal to 1 if individual j fills one or more Epivir or 
protease inhibitor prescriptions in quarter t and zero otherwise.  The main effect 
of the treatment is captured by the parameter 1θ  and the interaction of this effect 
with health status by 3θ .27   The vector of indicator variables ωt+1 is included to 
control for common changes over time in mortality. 
Our prediction that the treatments reduce mortality rates by a larger 
amount for sicker patients seems reasonable given the trends summarized in 
Figure 7.  In this figure, we plot quarterly mortality rates for the sickest 20 percent 
of patients (quintile 5), the next sickest 20 percent (quintile 4), and all other 
patients.  As the figure demonstrates, beginning in the first quarter of 1996, 
quarterly mortality rates in our sample fell substantially, with the largest drop 
apparent for the sickest patients.  By the first quarter of 1997, quarterly mortality 
rates had fallen by 70 percent in the fifth quintile (from 19.8 to 5.2 percent) and 
by 66 percent in quintile four (from 5.6 to 1.9 percent).  Consistent with this, the 
fraction taking Epivir/PI in the fourth quarter of 1996 was approximately similar 
in the two groups at 68 and 71 percent, respectively.  In contrast, just 40 percent 
of those in quintiles 1 through 3 filled a prescription for Epivir or protease 
inhibitors during this same quarter. 
Figure 7: Quarterly Mortality Rates by HIV/AIDS Severity: 1995Q1 - 1997Q1
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27 Thus the treatment effect function γ from equation (1) is equal to θ1 + θ3 * , 1ˆ j tD + . 
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Before proceeding to the results, it is worth considering two possible 
sources of bias that could be present when estimating this model.  First, our 
measure of health status is not perfect.  To the extent that two individuals with 
identical values of 1,ˆ +tjD  have different values of jtE , it is plausible that the 
person taking the treatment is on average in worse health.  This would most likely 
lead us to understate the health benefits of the treatment.  Second, even if our 
proxy for health status were perfect, if the effect of the treatments varies across 
individuals and individuals with the highest perceived benefits self-select into 
treatment, we might overstate the average benefits of the treatment.  We think this 
second source of bias is unlikely to be important, especially right after the 
treatments were released when patients and their health care providers had little 
experience with the new treatments.  In an effort to reduce both potential sources 
of bias, our identification strategy essentially uses HIV/AIDS patients from before 
the treatments were available as a comparison group for observably similar 
individuals who had the option to take Epivir/PI after it reached the market. 
The empirical results summarized in Table 4 examine the impact of 
Epivir/PI use on mortality.  The equation we estimate is similar to (4) above and 
the estimation sample is constructed from the sample of patients described in 
section 3, though because we are considering a two-year period rather than the 
full eleven-year period the number of individuals considered here is lower.   For 
person j to be included in our estimation sample in quarter t, he/she must be 
eligible for Medicaid in all three months of the current quarter and in all three 
months of the previous quarter, and must still be alive at the end of the current 
quarter.  There are 15,882 quarterly observations for 3,413 individuals, with the 
number of observations for each person ranging from one to eight.  All 
specifications are estimated as linear probability models and include eight quarter 
indicators. 
In the first column of Table 4, we report results that include only the time 
effects and the variable indicating whether the patient takes Epivir/PI in the 
current quarter.  Because sicker patients were likely to take these treatments, the 
magnitude of this estimate is likely to be biased down.   The statistically 
significant point estimate of -.0085 suggests that the treatments reduce mortality 
rates by less than one percentage point. This is much smaller in magnitude than 
the time series estimate presented above or than the estimates from random 
assignment clinical trials mentioned in section two.  The inclusion of 
demographic variables and the fraction of months in which the person was 
enrolled in Medicare lead to a small increase in this coefficient estimate to -.0113. 
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Table 4: The Heterogeneous Impact of Epivir/PI on Mortality 
(1) (2) (3) (4) (5) (6) 
Any Epivir/PI -.0085** -.0113*** -.0280*** -.0285*** -.0360*** .0115 
(.0038) (.0039) (.0039) (.0039) (.0040) (.0076) 
HIV Severity   .9731*** .9166*** .7819*** .9438*** 
(.0658) (.0742) (.0753) (.0822) 
Any Epivir/PI *       -.6387*** 
HIV Severity      (.1092) 
Previous HIV     .1051 .0400 .0489 
Severity    (.0665) (.0658) (.0639) 
Female  -.0202*** -.0126*** -.0123*** -.0141*** -.0130*** 
(.0038) (.0036) (.0036) (.0037) (.0037) 
Black -.0015 -.0023 -.0024 -.0012 -.0012 
(.0041) (.0036) (.0039) (.0038) (.0038) 
Age 15-24  -.0505*** -.0362*** -.0358*** -.0332*** -.0326*** 
(.0061) (.0065) (.0066) (.0077) (.0079) 
Age 25-34  -.0182*** -.0189*** -.0190*** -.0174*** -.0179*** 
(.0053) (.0050) (.0050) (.0050) (.0049) 
Age 35-44  -.0088* -.0106** -.0107** -.0090 -.0093** 
(.0051) (.0048) (.0048) (.0048) (.0048) 
Age 55-64  -.0082 -.0054 -.0054 -.0069 -.0062 
(.0086) (.0087) (.0088) (.0086) (.0083) 
Age 65+ -.0083 -.0019 -.0017 0.0005 .0021 
(.0098) (.0102) (.0102) (.0099) (.0101) 
Medicare  -.0085*** .0058 .0063* .0010 .0011 
(.0037) (.0033) (.0036) (.0036) (.0035) 
# Other RX Claims     .0016*** 0.0016*** 
   (.0002) (.0002) 
# Other Outpatient      .0002** .0002*** 
Claims    (.0001) (.0001) 
# Other Inpatient      .0005 .0006 
Claims    (.0008) (.0008) 
Quarters Included 95Q1- 95Q1- 95Q1- 95Q1- 95Q1- 95Q1-
# Observations 15882 15882 15882 15882 15882 15882 
Quarter Effects? Yes Yes Yes Yes Yes Yes 
R-squared 0.0057 0.0092 0.0779 0.0783 0.0919 0.0978 
# Individuals 3413 3413 3413 3413 3413 3413 
     
  
  
  
  
Sample includes all individuals with one or more HIV/AIDS claims in the quarter or in a previous 
quarter and who are eligible for Medicaid in all three months of this quarter, all three months of the 
previous quarter, and still alive at the end of the quarter.  Unit of observation is the person-quarter.  All 
specifications are estimated as linear probability models and include quarter fixed effects.  Standard 
errors are clustered by individual and included in parentheses.  
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Neither of these first two specifications includes our proxy for health 
status.  In the third specification we add the predicted mortality measure defined 
above to the set of explanatory variables.  The inclusion of this variable leads to 
an almost threefold increase in the magnitude of the estimate for the impact of 
Epivir/PI to -.0280.  The coefficient estimate of 0.9731 for the predicted mortality 
probability 1,ˆ +tjD  is not significantly different from one.  Because our measure of 
health status is undoubtedly measured with error, we include the value of j's 
predicted mortality probability from the preceding quarter in the fourth 
specification.  Interestingly the inclusion of this variable has virtually no impact 
on the other coefficient estimates, with the estimate for the effect of Epivir/PI 
increasing slightly in magnitude to -.0285.  In the fifth specification we add 
controls for the utilization of medical care for other conditions, which should to 
some extent capture additional dimensions of health status that are not captured 
by 1,ˆ +tjD .  The coefficients on these additional variables have the expected 
(positive) sign and their inclusion increases our estimate for the effect of Epivir/PI 
to -.0360, which is more than four times greater than the estimate from column 
one. 
In the sixth and final specification, we allow the effect of the treatments to 
vary with severity by interacting the treatment indicator jtE  with 1,ˆ +tjD .  If 
patients in worse health experience larger reductions in their mortality 
probabilities, one would expect a negative estimate for the coefficient on this 
interaction term.  And this is indeed what we find, with an estimate of -0.6387 for 
3θ  that is significant at the one percent level.  Including this interaction term 
reduces the magnitude of our estimate for 1θ  to a statistically insignificant .0115, 
implying that relatively healthy patients experienced no significant mortality 
decline as a result of taking the treatment. 
One possible concern with our estimates not mentioned above concerns 
the change in health care utilization induced by Epivir/PI.  To the extent the 
treatments reduce the number of hospital admissions or physician visits, this will 
reduce patients’ predicted mortality probabilities but this indirect effect would not 
be captured by the estimates for θ1 and θ3.  To account for this possibility, we 
estimated a companion set of specifications in which we “freeze” each patient’s 
predicted mortality probability at its value in the fourth quarter of 1995.  Our 
results using this alternative specification yielded similar though slightly larger 
results for the effect of the treatments. 
With our assumption that the effect of the treatment is linearly related with 
an individual’s predicted mortality probability, the estimates suggests an average 
mortality rate decline of approximately 68 percent (which is equal to the ratio 
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23 /θθ ), which is similar to the results reported above for the RACTs28 and for 
studies that had detailed clinical information on patients.  It therefore appears that 
our estimates do a good job of replicating the results for average impacts from 
studies with superior data or with the benefits of randomization.29  This is true 
despite the fact that sicker individuals clearly self-select into the treatment.  And 
in contrast to estimates from RACTs, our estimates allow us to estimate the extent 
to which the effects of the treatments varied across individuals in a real-world 
setting. 
One important limitation with the RACTs described above is that they do 
not consider the effect of new treatments on health care expenditures.  This is an 
important factor to consider when evaluating the value of any new medical 
innovation and is the focus of the next section. 
VI. The Impact of the New Treatments on Health Care Expenditures 
A. Changes in the Distribution of Medicaid Expenditures 
Theoretically, the effect of Epivir/PI on average short-term health care spending is 
ambiguous.  As shown in Figure 6, the release of Epivir/PI coincided with a 
significant increase in spending on prescription drugs, which was presumably 
driven both by the increase in use of ARVs and by the substantially higher prices 
of the new treatments relative to their predecessors.  But as this same figure 
shows, spending on other categories of medical care declined during this same 
period.  Which of these two effects dominated is not clear. 
In considering this issue, it is important to differentiate between 
individuals eligible only for Medicaid and their counterparts eligible for both 
Medicaid and Medicare.  For this latter group, the Medicare program is the 
primary payer for inpatient and outpatient care, though Medicaid does share the 
cost for most services.  Thus to the extent that Epivir/PI lowered spending on 
other health care services, one would expect – all else equal – to see a smaller 
decline (or a larger increase) in spending for those also “dual eligibles” who are 
also insured by the Medicare program. 
Figure 8 sheds some light on this issue.  In this figure, we plot average 
spending for dual eligibles and for their counterparts eligible only for Medicaid.  
As the figure shows, in the period leading up to the fourth quarter of 1995, there 
                                                
28 It is not strictly comparable to the RACT results because most of these studies considered the 
effect of just protease inhibitors when combined with AZT and Epivir.  This underscores the point 
raised above that we are capturing the effect of a combination of treatments rather than of one 
specific pharmaceutical treatment. 
29 Of course the average impact could have differed for the Medicaid population if, for example, 
they did not comply with the recommended treatment regimen as well as individuals in the 
RACTs. 
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were substantial differences in spending for the two groups.  Specifically, in the 
third quarter of 1995 average Medicaid spending was more than twice as high for 
those only covered by Medicaid ($6242 versus $3037) and both of these trends 
were fairly stable.  But beginning in the fourth quarter of 1995, spending for dual 
eligibles began to increase while the opposite occurred for those only covered by 
Medicaid.  By the final quarter of 1996, average spending for dual eligibles had 
increased by 36 percent (to $4122) versus a 16 percent decline for Medicaid-only 
recipients (to $5256).  This latter change suggests that the new treatments more 
than “paid for themselves” in the short term by reducing spending on other 
categories of medical care.  The benefits of this expenditure offset for dual 
eligibles are not as apparent in our Medicaid data because most inpatient and 
outpatient care for this group is financed by Medicare.30 
Figure 8: Average Medicaid Expenditures: Dual Eligibles vs. Medicaid Only
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These trends in average spending may mask important changes in the 
overall distribution of spending.  In Table 5 we list five different percentiles (30th, 
50th, 70th, 90th, and 95th) in the distribution of Medicaid expenditures.  If Epivir/PI 
                                                
30 The short-term spending declines suggested by this time series and estimated in the next section 
are qualitatively similar to the 10 percent average decline in spending estimated by Bozzette et al 
(2001) for a non-Medicaid population.  In a related study, Goldman et al (2001) estimate an 
average expenditure reduction of 31 percent that is attributable to more generous coverage of 
ARVs by state AIDS Drug Assistance Programs. 
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did reduce the use of other health care services, one might expect to detect larger 
declines in spending at the high end of the expenditure distribution.  In contrast, 
total spending might actually increase at the low end given that there would be 
relatively few health care services to offset for this group.  Consistent with this, 
the data summarized in Table 5 reveals that spending at the 30th and 50th
percentiles increased by 71 and 42 percent, respectively, from the third quarter of 
1995 to the fourth quarter of 1996.  But during that same period, Medicaid 
spending at both the 90th and the 95th percentiles declined by 24 percent.  The 
change at the 70th percentile lied between these two extremes, with a 12 percent 
increase during the period.  Thus, although there was very little change in average 
spending during the period when Epivir/PI was rapidly diffusing, there was a 
substantial change in the distribution of this spending. 
Table 5: Trends in the Distribution of Medicaid Expenditures: 1994Q1-1997Q4 
        
(1) (2) (3) (4) (5) (6) (7) (8) (9) 
        
Quarter 
Any 
Epiv/PI Mean 
Non-
Duals Duals 30th 50th 70th 90th 95th 
        
1994Q1 0.0% 5330 6135 3133 648 1643 3792 14653 23623 
1994Q2 0.0% 5183 5984 3088 584 1508 3554 14820 22610 
1994Q3 0.0% 5320 6283 3004 617 1574 3698 15245 24546 
1994Q4 0.0% 4783 5703 2572 604 1503 3627 13058 22039 
1995Q1 0.0% 5331 6380 2955 695 1775 4100 14646 23059 
1995Q2 0.0% 5190 6225 2986 652 1705 3998 14372 22581 
1995Q3 0.0% 5193 6242 3037 637 1737 3939 13910 23658 
1995Q4 6.7% 4973 6019 2937 651 1693 3895 13760 22893 
1996Q1 28.5% 5096 5893 3560 788 2045 4209 13042 21622 
1996Q2 37.0% 5037 5743 3703 889 2124 4450 13046 20835 
1996Q3 44.5% 4994 5648 3812 924 2275 4345 12035 20049 
1996Q4 50.2% 4841 5256 4122 1090 2473 4420 10679 18324 
1997Q1 52.8% 4790 5273 4002 1149 2610 4369 10643 17888 
1997Q2 56.0% 4803 5157 4257 1275 2775 4616 10459 16695 
1997Q3 55.3% 4836 5149 4373 1257 2770 4715 10154 17814 
1997Q4 55.2% 5011 5398 4460 1307 2860 4684 10164 19360 
        
        
        
        
        
        
        
        
Table summarizes Medicaid expenditure data for individuals in the 24 percent CA sample with 1 or 
more HIV/AIDS claims in current or previous quarter and still alive at the end of current quarter.  
Excludes those with one or more months in a Medicaid managed care plan or in one of the eight 
counties with a county-organized health system. Column (1) lists the fracton of individuals in the 
sample with one or more claims for Epivir/PI in the quarter.  Columns (2), (3), and (4) list average 
Medicaid spending for all individuals in the sample, those eligible for Medicaid only, and those 
eligible for Medicaid and Medicare, respectively.  Columns (5) through (9) list expenditures at five 
different points in the quarter specific Medicaid expenditure distribution.  Expenditures are inflation 
adjusted to November 2001 dollars.  
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B. Individual Level Estimates 
In this section, we present results from specifications analogous to (4) above, 
though in this case we focus on Medicaid spending.  Following previous research 
(Manning et al, 1987), we use the log rather than the level of health care spending 
as our outcome variable given that – as shown in Table 5 – spending is highly 
skewed to the right.31  We focus on individuals only eligible for Medicaid (thus 
excluding dual eligibles) given that our data does not include spending by the 
Medicare program for dual eligibles when estimating specifications of the 
following type: 
1,11,31,211,
ˆ**ˆ**)log()5( +++++ +++++= tjtjttjjttjjttj XDEDES ξωρσσσ
The parameters of particular interest in this equation are 1σ  and 3σ , which 
represent the main effect of Epivir/PI and the interaction of this effect with our 
proxy for health status 1,ˆ +tjD .   
Given that relatively sicker patients were more likely to take Epivir/PI 
following its release, one would expect that average Medicaid spending for 
individuals who took these treatments was higher on average than for their 
counterparts who did not.  The results presented in the first column of Table 6 
support this prediction, with a statistically significant estimate of 0.834 for 1σ
when no other covariates are included.  This estimate declines when additional 
covariates are included in the next four specifications, though it remains 
significantly positive.  This is not surprising given that Medicaid expenditures did 
increase at most points in the distribution as shown in Table 5. 
In the sixth specification we include the interaction of our treatment 
indicator with our proxy for health status.  As expected, the estimate for 3σ  is 
negative and is statistically significant, suggesting that sicker patients experienced 
a smaller increase in spending.  According to the model, individuals with a 
predicted mortality probability in excess of 27 percent experienced a decline in 
spending.  The estimates are similar in the final specification (7) in which we 
include both dual eligibles and individuals eligible only for Medicaid and 
therefore have a larger sample.32 
                                                
31 The logarithmic transformation substantially reduces the skewness in the data that can produce 
biased estimates given the assumption of a normally distributed error term. Given that more than 
90 percent of the person-quarter observations in 1995 and 1996 have strictly positive spending and 
there is little change in this fraction over time, we do not also consider the effect on the probability 
of strictly positive spending as the Manning et al (1987) study does.  
32 As was true for the mortality specifications, our results are qualitatively similar if we "freeze" 
each patient's predicted mortality probability at its level in the fourth quarter of 1995 for 
observations in 1996. 
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The results in this section demonstrate that the introduction and rapid 
diffusion of Epivir/PI in late 1995 and 1996 increased Medicaid spending for 
relatively healthy patients and for individuals also eligible for the Medicare 
program.  Despite this, the substantial reductions in spending for the sickest 
individuals more than offset this, so that average quarterly Medicaid spending in 
our sample declined by more than 7 percent in the year following the release of 
these treatments. 
Table 6: The Heterogeneous Impact of Epivir/PI on Medicaid Expenditures 
       
(1) (2) (3) (4) (5) (6) (7) 
       
Any Epivir/PI .834*** .796*** .682*** .668*** .633*** .901*** 1.094*** 
(.054) (.054) (.049) (.049) (.043) (.058) (.049) 
       
HIV Severity   7.371*** 5.782*** 3.411*** 4.192*** 4.262*** 
(.358) (.323) (.308) (.361) (.351) 
       
Any Epivir/PI *       
-
3.345*** -4.617*** 
HIV Severity      (.463) (.435) 
       
Previous HIV     3.109*** 2.323*** 2.348*** 2.360*** 
Severity    (.390) (.369) (.359) (.333) 
       
# Observations 8846 8846 8846 8846 8846 8846 14347 
Quarter Effects? Yes Yes Yes Yes Yes Yes Yes 
R-squared 0.0395 0.0510 0.1575 0.1677 0.2683 0.2723 0.2983 
# Individuals 2265 2265 2265 2265 2265 2265 3196 
Demographic 
 Controls? No Yes Yes Yes Yes Yes Yes 
Utilization  
Controls? No No No No Yes Yes Yes 
Quarters  
Included 
95Q1-
96Q4 
95Q1-
96Q4 
95Q1-
96Q4 
95Q1-
96Q4 
95Q1-
96Q4 
95Q1-
96Q4 
95Q1-
96Q4 
       
       
       
       
       
       
       
Sample includes all individuals with one or more HIV/AIDS claims in the quarter or in a previous 
quarter and who are eligible for Medicaid in all three months of this quarter, all three months of the 
previous quarter, and still alive at the end of the quarter.  Unit of observation is the person-quarter.  
Dependent variable is the log of Medicaid spending in the next period.  The key explanatory variable 
Any Epivir/PI is an indicator that equals one if an individual fills and Epivir or protease inhibitor 
prescription in the quarter and zero otherwise.  Standard errors are clustered by individual and included 
in parentheses.  
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VII. The Impact on Long-Term Medicaid Spending and the Cost per Life-
Year Saved  
In this section we simulate the impact of Epivir/PI on long-term health care 
spending in the Medicaid program.  There are two factors that diverge when 
calculating these costs.  First, our results suggest that average spending declined 
when these treatments were introduced.  In contrast, the large reduction in 
mortality generated by Epivir/PI use increased life expectancy, and hence the 
amount of time that individuals were eligible for Medicaid.33  In this section, we 
build an illustrative model that allows us to capture these two opposing factors in 
a simple calculation. 
Consider an HIV positive patient that has progressed in their illness to the 
point that physicians would recommend Epivir/PI use, which we label as quarter 
0.  Suppose in the absence of ARVs, a patient will have medical expenditures of 
M0 in period 0, and for simplicity, assume this amount grows at a real rate of ρ per 
quarter.  Patients are assumed to die at a rate of δ in each quarter and this rate is 
assumed to be constant over time.  If r is the quarterly interest rate, the discounted 
expected lifetime costs LT0 for this patient in the absence of antiretroviral 
treatments are:  
t
t
t
o rMLT )1()]1/()1[()6(
0
0 δρ −++= ∑∞=
For simplicity, assume that ρ is equal to r34 and therefore, that discounted lifetime 
costs equal M0/δ. When Epivir/PI was introduced, assume baseline costs and the 
mortality rates changed to aM 0 and δ
a respectively, and therefore, lifetime costs 
would then be aM 0 /δ
a.  The increase in life expectancy in quarters is simply [1/δa
– 1/δ] and the corresponding change in lifetime costs is [ aM 0 /δa - M0/δ].  Dividing 
this number by 4[1/δa – 1/δ] produces the cost per life year saved. 
Prior to the introduction of the new treatments, the average quarterly 
mortality rate in our sample was 7 percent and average spending per person-
quarter was equal to $6242.  Our results from above suggest that Epivir/PI 
reduced mortality rates by 68 percent and average Medicaid spending per quarter 
                                                
33 As Meltzer (1997) outlines, there is some controversy about whether future medical costs 
should be considered in medical cost-effectiveness studies.  Meltzer argues that for cost-
effectiveness studies to be consistent with utility maximization, they must include all future 
lifetime costs, including non-medical expenses.  At the other extreme, others argue that only future 
medical costs directly related to the illness should be included in these calculations.  Given 
available data, we examine all future medical costs but do not include non-medical expenses.   
34 This assumption seems reasonable given that our estimate of the average growth rate in 
individual-specific quarterly Medicaid spending in both the pre and post periods was 
approximately 1 percent. 
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by 16 percent.  Given our simplifying assumptions, this implies that Epivir/PI 
increased the average present value of Medicaid spending from $89,000 to 
$234,000 and life expectancy from 3.6 to 11.2 years, with a corresponding cost 
per life year saved of approximately $19,000.35  This is substantially lower than 
recent estimates of the average individual's valuation of a life-year, which Cutler 
and Richardson (1998) estimate lies between $75 thousand and $150 thousand. 
We should note that we make a number of strong assumptions, including a 
constant mortality rate (rather than one that increases over time) and that the 
discount rate is equal to the growth in quarterly Medicaid expenditures.   It is 
worth noting, however, that the marginal cost per life year saved calculation is not 
particularly sensitive to the assumed values of M0 and Ma0.  If we assume there is 
no change in spending associated with ARVs then the cost per life year saved 
increases to roughly $25,000. Likewise, the results are not very sensitive to the 
precise drop in mortality produced by ARVs.  Thus even if we relax one of these 
or our other assumptions, the four ARVs studied here are well within the range of 
what is considered to be cost effective. 36 
The estimates for this treatment do not apply to other ARVs or to other 
new health care treatments.  Indeed as shown in Figure 5, since the utilization of 
Epivir/PI settled to its new equilibrium in early 1997, there has been little further 
decline in mortality rates among Medicaid patients with HIV/AIDS.  This has 
been true despite a consistent increase in pharmaceutical spending in the last 
several years of our sample, which increased from $2,385 in the second quarter of 
1997 to almost $3,900 per quarter in 2001.  However, before inferring anything 
about cost-effectiveness from these simple trends, there are two important issues 
to consider.  First, mortality rates may have increased had it not been for the 
arrival of the new ARVs, as the virus could have become more resistant to a 
specific drug over time.  Second, there may be other improvements in morbidity 
that are not captured by mortality rates alone.37 
                                                
35 This estimate is similar to estimates presented by Freedberg et al (2001).  The authors use 
estimates from RACTs to simulate the cost-effectiveness of three-drug anti-retroviral regimens.  
They estimate that such a regimen costs $13,000 to $23,000 per quality adjusted life year in real 
1998 dollars.  The increase in life expectancy is just half as large as the 15 year impact simulated 
by Philipson and Jena (2006) using the results from previous studies.  However, their estimate 
includes the increase in life expectancy from the time than an individual first contracts HIV.  As 
noted above, when individuals are first observed in our sample they may already have had HIV for 
several years. 
36 Our results further assume that the short term mortality and expenditure effects that we estimate 
will persist in the long term.  To the extent that the treatments become less effective over time, 
lead to complications from other health conditions, and so forth, this assumption will not be 
accurate. 
37 While we have in this study focused on mortality, one could use the claims data to construct 
measures of morbidity such as the presence of other conditions or time spent in inpatient care.  
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VIII. Discussion 
The steady increase in health care spending in recent years and that is projected 
for the coming decades suggests that greater scrutiny may be given to the benefits 
of new and more expensive health care treatments.  Potential sources of data for 
these analyses are the claims data sets from insurers such as Medicare, Medicaid, 
or private insurance companies.  These data sets have large sample sizes, have 
detailed information on individuals’ treatments, and have very accurate data on 
expenditures.  It is, however, difficult to reliably estimate the effects of interest 
with this data because of the absence of clinical information that would allow one 
to control for baseline health status and because treatment decisions are 
endogenous. 
In this study we investigate whether the use of individual-level 
administrative data from before and after the release of a new health care 
treatment can be used to obtain credible estimates of its effect on both health care 
spending and health outcomes and how this varies across individuals. Our 
findings for the average treatment effects are in line with those from previous 
studies that use randomized research designs or that have the benefit of detailed 
clinical information.  Specifically, our results suggest that the treatments led to a 
68 percent reduction in mortality rates among the individuals who took them.  In 
contrast to these earlier studies, we can investigate the extent to which the use of 
the treatments varies across individuals and how the effects of the treatments vary 
as well.  Additionally, we can consider the effect on health care expenditures. 
When interpreting the results from our empirical analyses, it is important 
to bear in mind a number of limitations.  First, our model assumes that the effect 
of ARVs is linearly related with our measure of health status.  Second, to the 
extent that unobserved factors are correlated with the ARV treatment decision, 
our estimates will be biased. Third, changes in the observable characteristics of 
those with HIV during our study period raise the possibility of composition bias.  
Fourth, our estimates do not account for possible changes in the effectiveness of 
ARVs over the long term.  And finally, our estimates do not consider factors such 
as firm R&D costs or treatment-induced changes in risky behavior, which 
represent important components of a more comprehensive accounting of overall 
treatment benefits and costs. 
But the results from our primary specifications, combined with the trends 
in mortality and in the distribution of Medicaid spending, strongly suggest that 
one can use readily available administrative data from a real-world setting to 
                                                                                                                                    
There will inevitably be certain measures of health status that one cannot capture in claims data, 
and the importance of this limitation will depend on the treatment being considered. 
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obtain credible estimates of the effect of new treatments on both health care 
spending and health outcomes and how these effects vary across individuals.  An 
important benefit of using data from before and after the introduction of new 
treatments is that one can examine how the distribution of key outcome variables 
evolves as the treatments diffuse, and use this as a check on the individual-level 
estimates.  Our approach is most well-suited to the evaluation of treatments that 
diffuse rapidly and that are likely to affect health status primarily in ways that can 
be captured in administrative data. 
Appendix Figure 1: Rate of Non-Mortality Exit for Medicaid HIV/AIDS Sample
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